Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Rated “Reduce” by Wall Street Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned a consensus rating of “Reduce” from the twenty-one brokerages that are presently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $22.59.

A number of analysts have issued reports on the stock. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, July 9th. Weiss Ratings raised shares of Sarepta Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Wall Street Zen cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Royal Bank Of Canada cut their target price on shares of Sarepta Therapeutics from $19.00 to $17.00 and set a “sector perform” rating on the stock in a research note on Thursday, October 8th. Finally, HC Wainwright reiterated a “sell” rating and set a $5.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 5th.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $17.73 on Tuesday. Sarepta Therapeutics has a 1-year low of $14.68 and a 1-year high of $24.68. The stock has a market cap of $1.87 billion, a PE ratio of -6.11, a P/E/G ratio of 0.31 and a beta of 0.38. The firm has a 50-day simple moving average of $19.30 and a two-hundred day simple moving average of $18.68. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%. The company had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. During the same quarter in the previous year, the company earned $2.02 earnings per share. The firm’s quarterly revenue was down 34.3% compared to the same quarter last year. As a group, analysts forecast that Sarepta Therapeutics will post 3.27 EPS for the current year.

Institutional Trading of Sarepta Therapeutics

Hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. lifted its stake in Sarepta Therapeutics by 7.8% in the first quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 636 shares during the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of Sarepta Therapeutics by 3.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 28,787 shares of the biotechnology company’s stock worth $626,000 after acquiring an additional 875 shares during the period. Baird Financial Group Inc. increased its holdings in shares of Sarepta Therapeutics by 7.6% in the 2nd quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company’s stock worth $230,000 after acquiring an additional 901 shares during the period. Meeder Asset Management Inc. bought a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $27,000. Finally, Rockefeller Capital Management L.P. lifted its position in Sarepta Therapeutics by 98.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 4,104 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 2,034 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.